The litigation centers on claims that ARS Pharmaceuticals provided overly confident projections regarding a July 1, 2026, formulary effective date for its neffy treatment. While management frequently touted the drug's commercial coverage—citing 93% overall access and citing the CVS Caremark approval process as being in its final stages—the complaint alleges these statements lacked necessary warnings about potential delays.

When the company revealed on June 24 that CVS Caremark had deferred its decision until January 2027, the stock plummeted from $10.54 to $8.02. Plaintiffs argue that defendants relied on generalized risk disclosures while omitting specific, known hurdles that could push the decision into the following year, effectively causing investors to miss out on critical allergy season market windows. Attorney Joseph E. Levi, representing the class, stated that generic cautionary language cannot replace clear disclosure of concrete procedural risks that directly impact a company’s access strategy.